Biogen reported positive results from Part A of the AMETHYST Phase 2/3 study of litifilimab in cutaneous lupus erythematosus (CLE), supporting continued development. Litifilimab — described as the first humanized IgG1 monoclonal antibody targeting BDCA2 — can advance toward later-stage testing and, if subsequent data confirm efficacy and safety, represent a new dermatologic autoimmune asset for Biogen.
Biogen reported positive results from Part A of the AMETHYST Phase 2/3 study of litifilimab in cutaneous lupus erythematosus (CLE), supporting continued development. Litifilimab — described as the first humanized IgG1 monoclonal antibody targeting BDCA2 — can advance toward later-stage testing and, if subsequent data confirm efficacy and safety, represent a new dermatologic autoimmune asset for Biogen.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
